Zobrazeno 1 - 10
of 358
pro vyhledávání: '"Harry P Erba"'
Autor:
Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172640 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0166891.].
Externí odkaz:
https://doaj.org/article/0c0b3c70b8574ea581f5c056b9ae8f35
Autor:
Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0166891 (2016)
Approximately fifty percent of patients with acute myeloid leukemia can be cured with current therapeutic strategies which include, standard dose chemotherapy for patients at standard risk of relapse as assessed by cytogenetic and molecular analysis,
Externí odkaz:
https://doaj.org/article/57481fa391aa4b97aff8e60674a1d1ae
Autor:
Era L. Pogosova-Agadjanyan, Xing Hua, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba, Matthew P. Fitzgibbon, Isaac C. Jenkins, Min Fang, Stanley C. Lee, Anna Moseley, Jasmine Naru, Jerald P. Radich, Jenny L. Smith, Brooke E. Willborg, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-12 (2023)
Abstract Background Studies have not systematically compared the ability to verify performance of prognostic transcripts in paired bulk mononuclear cells versus viable CD34-expressing leukemic blasts from patients with acute myeloid leukemia. We hypo
Externí odkaz:
https://doaj.org/article/068af1ff03784be8bc61228665d49697
Autor:
Laura W. Dillon, Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H. Smith, Elizabeth Schmidt, Charles C. Valentine III, Jesse J. Salk, Brent L Wood, Harry P. Erba, Jerald P. Radich, Christopher S. Hourigan
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes, MRD assessment has yet to be standardized or routinely incorporated into
Externí odkaz:
https://doaj.org/article/5ddca69089a4412bafc0c569c3e4ed97
Autor:
Richard Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Aziz Benzohra, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
Publikováno v:
HemaSphere, Vol 7, p e61150fb (2023)
Externí odkaz:
https://doaj.org/article/161ac30cf9634f0ab1e0c386b591f284
Autor:
Mark J Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C.N. Chang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl
Publikováno v:
HemaSphere, Vol 7, p e446548f (2023)
Externí odkaz:
https://doaj.org/article/def63e6658704a3a951c965be0108d02
Autor:
Christina M. Termini, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba, Min Fang, Stanley C. Lee, Jasmine Naru, Era L. Pogosova-Agadjanyan, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/4c2f1cc13a4d4e82997fde8282f05c18
Autor:
Megan Othus, Guillermo Garcia-Manero, John E. Godwin, James K. Weick, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
We have previously shown that complete response (CR) rates and overall survival of patients with acute myeloid leukemia have improved since the 1980s. However, we have not previously evaluated how the length of first CR (CR1) has changed over this ti
Externí odkaz:
https://doaj.org/article/de1cfaf03ff2478e8cfd157adae95ad7
Autor:
Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 58-68 (2020)
Abstract Diagnostic and molecular genetic testing are key in advancing the treatment of acute myeloid leukemia (AML), yet little is known about testing patterns outside of clinical trials, especially in older patients. We analyzed diagnostic and mole
Externí odkaz:
https://doaj.org/article/b36efed85da84efcbaf5ae149d394d44
Autor:
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Publikováno v:
Blood Advances, Vol 3, Iss 13, Pp 1939-1949 (2019)
Abstract: This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid leukemia (AML). AM
Externí odkaz:
https://doaj.org/article/9ffe38dae5d04e0caf33a13f3a09fb49